Jenburkt Pharma AGM: 99.99% Votes, ₹20.70 Dividend

Near-unanimous shareholder approval at 41st AGM

Jenburkt Pharmaceuticals Limited said shareholders approved all resolutions at its 41st Annual General Meeting (AGM) held on September 4, 2026, with 99.99% support across agenda items. The voting results were filed with the BSE under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Among the key outcomes were the adoption of FY26 financial statements, declaration of a final dividend, and approvals related to appointments. The filings also highlight a wide gap between promoter participation and public shareholder participation. While the outcome was decisive, the voting data provides a clearer picture of who actually voted.

Dividend of ₹20.70 per share (207%) cleared for FY26

One of the central resolutions was the declaration of a final dividend of ₹20.70 per equity share for FY26. The company described this as a 207% payout on the ₹10 face value. The dividend resolution was approved with 19,26,143 votes in favour and 2 votes against, translating into 99.99% support. Jenburkt had stated that any dividend declared will be disbursed within 30 days following the AGM. The record date and cut-off date for dividend eligibility were the same, set as August 28, 2026. This linkage matters for shareholders because eligibility to receive the dividend is determined by holdings as of that date.

Dilip H. Bhuta re-appointed as CFO for five years from April 2027

Shareholders also approved the re-appointment of Dilip H. Bhuta as Chief Financial Officer for a five-year term effective April 2027. This approval came through a special resolution that recorded 19,25,543 votes in favour and 2 votes against, again reflecting 99.99% support. The AGM agenda also included a resolution to re-appoint D.H. Bhuta as a director, which passed with the same vote count and support percentage. The voting pattern indicates that the small number of dissenting votes was consistent across multiple resolutions. The company’s filings show that the appointments formed a significant part of the meeting’s business.

Voting participation: promoters dominated, public turnout remained thin

The scrutinizer’s report shows that the promoter group held 2,057,450 shares. Promoters cast 1,916,350 votes in favour across key resolutions, representing 93.14% participation from their holdings. Public non-institutional shareholders held 23,54,217 shares but polled only 9,795 votes, which the company reported as 0.42% participation. Institutional public shareholders did not vote. The result was a meeting where the outcome was effectively determined by promoter turnout, with limited engagement from the wider public shareholder base. The data also shows there were two votes cast against the financial statements and dividend resolutions.

How the meeting was conducted: VC participation, no physical attendance

Jenburkt stated that a total of 7,332 shareholders were on record. No shareholders attended physically, while 51 participants joined via Video Conferencing (VC). The AGM was conducted via VC/OAVM, as outlined in the company’s notice. The meeting time was scheduled at 3:30 p.m. IST on September 4, 2026. The disclosures emphasise process compliance, including voting windows and eligibility criteria. These operational details are typically critical during high-dividend declarations or key management appointments.

E-voting process and deadlines shareholders had to follow

Voting was enabled through the National Securities Depository Limited (NSDL) e-voting system. Jenburkt specified that voting rights were proportionate to the paid-up value of equity shares held as on the cut-off date. The remote e-voting window opened three days before the AGM and closed the day before the meeting. The company also clarified that once a vote is cast through remote e-voting, it cannot be changed. Shareholders who voted remotely could still attend the AGM via VC/OAVM, but they could not vote again. Those who attended the meeting without voting remotely could vote during the AGM or within 15 minutes after the AGM concluded.

Key resolutions and voting outcome summary

The company’s consolidated voting results show near-identical outcomes across resolutions, with only two votes recorded against multiple items.

Record date, cut-off date, and the NSDL window

Jenburkt fixed Friday, August 28, 2026 as both the record date for dividend eligibility and the cut-off date for voting. Shareholders holding shares as of that date were eligible to vote on all resolutions placed before the AGM. The company’s notice set the remote e-voting schedule from September 1 to September 3, 2026. These dates and times are important in practice because shareholders who buy shares after the cut-off date do not get voting rights for the meeting and may not be eligible for dividend benefits tied to the record date.

Market check: reported share price on AGM date

The filings also carried a snapshot of the company’s reported market prices on September 4, 2026. Jenburkt Pharmaceuticals’ share price was stated as ₹1,038.8 on NSE and ₹1,034.4 on BSE as on 4/9/2026. While AGM voting results do not directly translate into immediate price movement, the information provides context for investors tracking dividend announcements and governance outcomes. The company’s BSE scrip code was referenced as 524731 in the disclosures. The reporting around the AGM and voting results was positioned as a compliance update to exchanges.

Why these AGM outcomes matter for shareholders

The AGM outcomes were market-relevant primarily because they formally approved the FY26 dividend and key appointments through an exchange-disclosed voting process. The promoter participation rate of 93.14% contrasted sharply with the 0.42% polling by public non-institutional shareholders. This pattern shows that, in this meeting, the promoter group’s voting behaviour largely shaped the final outcome. For public shareholders, the bigger practical takeaway was procedural: holdings as of August 28, 2026 determined both voting rights and dividend eligibility. The company also reiterated that dividend disbursement would be completed within 30 days of the AGM, if declared.

Conclusion

Jenburkt Pharmaceuticals’ 41st AGM on September 4, 2026 ended with all resolutions passing with 99.99% support, including the FY26 final dividend of ₹20.70 per share and the five-year CFO term for Dilip H. Bhuta effective April 2027. The scrutinizer’s data showed strong promoter participation and low public voting turnout. The company’s notice and exchange filings also set out the process milestones, including August 28, 2026 as the cut-off and record date, and the NSDL remote e-voting window from September 1 to September 3. The next operational step disclosed in the notice is dividend disbursement within 30 days after the AGM.